Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma

Pier Luigi Zinzani, Armando Santoro, Arturo Chiti, Secondo Lastoria, Antonio Pinto, Lugi Rigacci, Giovanni Barosi, Martina Pennisi, Paolo Corradini

Research output: Contribution to journalArticle

Abstract

Programmed death 1 (PD-1) blocking antibodies now represent a major advance in the treatment of patients with classical Hodgkin lymphoma (cHL) who relapse after autologous stem cell transplantation (ASCT) and pre- and/or post-ASCT brentuximab vedotin or after at least three lines of therapy. However, uncertainties still remain on the optimal use of these agents in refractory Hodgkin disease. A panel of experts was convened to produce a consensus document aimed at providing practice recommendations for the optimal use of PD-1 blocking antibodies in cHL, especially on pretreatment selection and evaluation of cHL patients’ response and treatment length, management of PD-1 blockade therapy–treated patients, evaluation and management of toxicity. Our hope is that these recommendations might help hematologists to improve optimal management of patients with pretreated cHL.

Original languageEnglish
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - Jan 1 2018

Keywords

  • checkpoint inhibitors
  • Hodgkin lymphoma
  • practice guidelines

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma'. Together they form a unique fingerprint.

  • Cite this